NASDAQ: CVKDCadrenal Therapeutics Inc Stock
$2.35-0.07 (-2.89%)
Updated Jul 15, 2026
CVKD Price
$2.35
Fair Value Price
$2.01
Market Cap
$6.74M
52 Week Low
$2.29
52 Week High
$14.64
P/E
-0.42x
P/B
3.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.89M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.59
Operating Cash Flow
-$11M
Beta
1.01
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CVKD Overview
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CVKD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CVKD
Ranked#346 of 464
Ranked#346 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $239.32 | A | |
| $10.73 | A | |
| $16.10 | A |
Be the first to know about important CVKD news, forecast changes, insider trades & much more!
CVKD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CVKD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CVKD ($2.35) is overvalued by 16.91% relative to our estimate of its Fair Value price of $2.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CVKD ($2.35) is not significantly undervalued (16.91%) relative to our estimate of its Fair Value price of $2.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CVKD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CVKD due diligence checks available for Premium users.
Valuation
CVKD fair value
Fair Value of CVKD stock based on Discounted Cash Flow (DCF)
Price
$2.35
Fair Value
$2.01
Overvalued by
16.91%
CVKD ($2.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CVKD ($2.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CVKD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CVKD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.42x
Industry
18.63x
Market
9.1x
CVKD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.75x
Industry
5.46x
CVKD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CVKD's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.5M
Profit Margin
0%
CVKD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.9M
Liabilities
$1.1M
Debt to equity
0.59
CVKD's short-term assets ($2.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CVKD's short-term assets ($2.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CVKD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
$0.0
Financing
$1.3M
CVKD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CVKD vs Biotech Stocks
Cadrenal Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.